Kintara Therapeutics, Inc. says VAL-083 treatment arm in the Phase 2/3 clinical trial for glioblastoma multiforme has now been activated in 15 US sitesProactive Investors • 05/26/21
Kintara Therapeutics draws Buy recommendation from Aegis Capital which maintains a $7 price targetProactive Investors • 05/19/21
Kintara Therapeutics ends fiscal 3Q with cash and cash equivalents of about $15.7MProactive Investors • 05/14/21
Kintara Therapeutics Announces Fiscal Third Quarter 2021 Financial Results and Provides Corporate UpdatePRNewsWire • 05/14/21
Kintara Therapeutics appoints corporate finance veteran Tamara Seymour as its board directorProactive Investors • 05/04/21
Kintara Therapeutics says interim Phase 2 study data on VAL-083 shows its potential as game-changing treatment option for GBM patientsProactive Investors • 04/12/21
Kintara Presents Updates on Two Phase 2 Clinical Trials at the 2021 American Association for Cancer Research Annual MeetingPRNewsWire • 04/12/21
Kintara Therapeutics to Participate in Maxim Group's 2021 Emerging Growth Virtual ConferencePRNewsWire • 03/10/21
Kintara Therapeutics appoints Dr Mario Lacouture to its scientific advisory board for cutaneous metastatic breast cancerProactive Investors • 03/03/21
Kintara Therapeutics Concludes Enrollment In Recurrent Arm Of VAL-083 Mid-Stage Brain Cancer StudyBenzinga • 02/17/21
Kintara Therapeutics enrolls last patient in Phase 2 VAL-083 trial for recurrent glioblastoma multiformeProactive Investors • 02/17/21
Kintara Therapeutics says it has enough cash to fund its planned operations into the fourth quarter of calendar 2021Proactive Investors • 02/12/21
Kintara Therapeutics Announces First Fiscal Quarter 2021 Financial Results and Recent Corporate UpdatesPRNewsWire • 11/13/20
Kintara Therapeutics Announces Additional $2.4 Million Private Placement Priced At-The-MarketPRNewsWire • 08/21/20
Kintara Therapeutics (formerly DelMar Pharmaceuticals) Regains Compliance with NASDAQ Minimum Bid Price RequirementPRNewsWire • 08/21/20